中国经济网北京11月8日讯 北京证券交易所上市委员会2025年第29次审议会议于昨日上午召开，审议结 果显示，浙江海圣医疗器械股份有限公司（以下简称"海圣医疗"）首发符合发行条件、上市条件和信息 披露要求。这是今年过会的第71家企业（其中，上交所和深交所一共过会43家，北交所过会28家）。 海圣医疗的保荐机构为中信证券股份有限公司，签字保荐代表人为蔡斌、董超。这是中信证券今年保荐 成功的第8单IPO项目。此前，2月21日，中信证券保荐的江苏汉邦科技股份有限公司过会；4月18日， 中信证券保荐的广州瑞立科密汽车电子股份有限公司过会；7月11日，中信证券保荐的北矿检测技术股 份有限公司过会；8月14日，中信证券保荐的西安奕斯伟材料科技股份有限公司过会；9月19日，中信证 券保荐的苏州市新广益电子股份有限公司过会；9月26日，中信证券保荐的苏州摩尔线程智能科技（北 京）股份有限公司过会；10月15日，中信证券保荐的厦门优迅芯片股份有限公司过会。 海圣医疗是面向全球的麻醉、监护类医疗器械综合产品提供商，主营业务为麻醉、监护类医疗器械产品 的研发、生产和销售，产品已广泛应用于麻醉科、ICU病房、急诊科等科室的终端临床需 ...

证券时报·数据宝统计，根据深交所、上交所、北交所上市委会议公告， 将有5家企业首发事项上会。 从拟上市板来看，强一股份拟科创板IPO；陕西旅游拟沪市主板上市；通宝光电、国亮新材等3家企业 拟北交所IPO。 拟募资额方面， 即将上会的5家企业中，拟募集资金最多的是陕西旅游，预计募集资金15.55亿元，募资 拟投向泰山秀城（二期）项目、收购太华索道股权项目、收购瑶光阁股权项目、少华山南线索道项目、 收购少华山旅游索道项目、太华索道游客中心项目、太华索道服务中心项目等项目。其次是强一股份、 海圣医疗，拟募资金额分别为15.00亿元、3.70亿元。地域分布看，即将上会企业中，江苏省有2家企业 上榜，陕西省、浙江省、河北省分别有1家企业上榜。 1家主板公司拟上会 即将上会的IPO公司 | 简称 | 会议日期 | 拟上市板 | 拟发行数量（万 | 拟募资金额（亿 | 注册 | 保荐机构 | | --- | --- | --- | --- | --- | --- | --- | | | | 块 | 股） | 元） | 地 | | | 通宝光 | 2025.11.13 | 北交所 | 1879.34 | 3.30 | 江苏 ...

11月7日（周五），浙江海圣医疗器械股份有限公司将迎来北京证券交易所上市委员会审议，正式进入 IPO关键审核阶段。据其招股书显示，公司专注于麻醉、监护类医疗器械的研发、生产和销售，已搭建 起麻醉类、监护类、手术及护理类三大类产品矩阵，涵盖气道与呼吸管理、生命信息监测、椎管及神经 阻滞等八大系列，产品广泛应用于全国上千家三级医院及数千家医疗机构，其中三甲医院超600家，包 括中国医学科学院北京协和医院、上海交通大学医学院附属瑞金医院等知名机构。 从海圣医疗的业务布局来看，其核心产品已覆盖国内众多核心医疗机构，技术储备与产能规划也与行业 发展趋势高度契合。未来随着募集资金项目的逐步落地，公司在麻醉、监护类医疗器械领域的产能规模 与技术转化能力将进一步提升，有望持续巩固细分市场优势。 此前一轮问询中，监管机构关注公司销售费用率合理性。公司在问询回复中明确，报告期内销售费用主 要用于学术推广、经销商培训及市场渠道维护，费用率与同行业可比公司维力医疗、三鑫医疗等水平基 本一致。由于医疗器械行业需通过专业学术交流传递产品临床价值，相关投入均围绕终端需求对接展 开，且建立了严格的费用审批与管控机制，确保资金使用合规高效，充 ...

Core Insights - Five companies are set to present their IPO applications, with a focus on various sectors including tourism, medical devices, and advanced manufacturing [1] Group 1: Upcoming IPOs - Xi'an Tourism plans to raise 1.555 billion yuan, targeting multiple projects including the Taishan Xiucheng Phase II and acquisitions related to tourism infrastructure [1] - Qiangyi Co. aims to raise 1.5 billion yuan, specializing in MEMS probe card manufacturing, a niche technology in the semiconductor industry [4] - Zhixin Co. intends to raise 1.329 billion yuan, focusing on automotive welding components and related mold development [2] - Haiseng Medical seeks to raise 370 million yuan, engaged in the R&D and production of anesthesia and monitoring medical devices [5] - Guoliang New Materials plans to raise 175 million yuan, providing high-temperature industrial refractory material solutions [5] Group 2: Company Profiles - Xi'an Tourism integrates tourism performances, cable cars, dining, and project investment and management [3] - Qiangyi Co. is one of the few domestic manufacturers with the capability to produce MEMS probe cards in bulk [4] - Zhixin Co. specializes in the development, processing, and sales of automotive welding parts and molds [2] - Haiseng Medical focuses on high-tech medical devices for anesthesia and monitoring, serving critical care departments [5] - Guoliang New Materials offers comprehensive solutions for high-temperature refractory materials [5]

海圣医疗是面向全球的麻醉、监护类医疗器械综合产品提供商，主营业务为麻醉、监护类医疗器械产品的研发、生产和销售，产品已广泛应用于麻醉科、 ICU病房、急诊科等科室的终端临床需求。 11月7日，浙江海圣医疗器械股份有限公司（下称"海圣医疗"）将北交所IPO上会，公开发行不超过1129.41万股。 笔者注意到，海圣医疗的业绩主要是通过经销模式所获，每年至少有8成的收入是通过经销商。需要说明的是，虽然经销商在销售链路中占据核心地位，但 其结构却暗藏风险，海圣医疗每年新增与退出的经销商数量均超200 家，群体流动性极大，且退出经销商的毛利率始终高于新增经销商，2024年两者差额更 是达到4.18个百分点，单位利润差异显著。 费用方面，近三年半海圣医疗的销售费用合计约1.05亿元，几乎是研发费用的两倍，而销售费用率不仅持续增长至10.63%，还始终远超同行6.25%的均值， 费用控制效率落后。进一步拆解可见，超6成销售费用用于职工薪酬，且公司销售人员占比远高于维力医疗、三鑫医疗等同行，人均薪酬也处于较高水平， 但人均创收却显著低于这些可比公司，"高投入低产出"的人员效率反差明显。 年换200+经销商 2022年-2024 ...

Core Viewpoint - This week (November 3 to November 7), five companies are scheduled for IPO meetings, with a total fundraising target of approximately 38.71 billion yuan [1]. Group 1: Upcoming IPOs - Five companies are set to present their IPO applications: Shaanxi Tourism and Zhixin Co. for the Shanghai main board, and Guoliang New Materials, Haiseng Medical, and Qilong Ocean for the Beijing Stock Exchange [1][2][4]. - Shaanxi Tourism aims to raise the highest amount of 1.555 billion yuan, with funds allocated for multiple projects including the Taishan Xiucheng Phase II project and various acquisitions [1][3]. - Zhixin Co. plans to raise 1.329 billion yuan, while Qilong Ocean aims for 382 million yuan [1]. Group 2: Company Profiles - Shaanxi Tourism integrates tourism performances, cable cars, dining, and project investment and management [3]. - Zhixin Co. specializes in the development, processing, production, and sales of automotive welding parts and related molds [2]. - Haiseng Medical focuses on the research, production, and sales of anesthesia and monitoring medical devices, serving various clinical needs [4]. - Guoliang New Materials provides high-temperature industrial refractory material solutions [4]. - Qilong Ocean is involved in the research, production, and sales of marine drilling riser systems and underwater oil and gas equipment testing services [4].

Core Viewpoint - The upcoming IPO review period from November 3 to November 7 will feature five companies aiming to raise a total of 3.812 billion yuan [1]. IPO Companies Overview - Five companies are scheduled for IPO review: - Qilong Ocean (Shandong) aims to raise 381.889 million yuan, with a net profit of 50.67 million yuan [2][5]. - Zhixin Co., Ltd. plans to raise 1.329 billion yuan, reporting a net profit of 203.964 million yuan [2][10]. - Shaanxi Tourism intends to raise 1.555 billion yuan, with a net profit of 621.578 million yuan [2][15]. - Haiseng Medical (Zhejiang) seeks to raise 370.425 million yuan, with a net profit of 70.918 million yuan [2][20]. - Guoliang New Materials (Hebei) aims to raise 175.022 million yuan, reporting a net profit of 70.965 million yuan [2][25]. Fundraising Adjustments - Guoliang New Materials reduced its fundraising target from 301 million yuan to 175 million yuan, eliminating the R&D center project and adjusting working capital needs [3]. Financial Performance - Qilong Ocean reported total assets of 432.166 million yuan and a net profit of 49.075 million yuan for the first half of 2025 [7]. - Zhixin Co., Ltd. had total assets of 427.830 million yuan and a net profit of 9.448 million yuan for the first half of 2025 [12]. - Shaanxi Tourism's total assets reached 214.426 million yuan with a net profit of 24.707 million yuan for the first half of 2025 [17]. - Haiseng Medical reported total assets of 519.449 million yuan and a net profit of 35.494 million yuan for the first half of 2025 [23]. - Guoliang New Materials had total assets of 1.520 billion yuan and a net profit of 41.497 million yuan for the first half of 2025 [26]. Investment Projects - Qilong Ocean's main investment project is the high-performance large-diameter riser pipe production project, with a total investment of 381.889 million yuan [9]. - Zhixin Co., Ltd. plans to expand its production capacity and technology for automotive welding components, with a total investment of 1.329 billion yuan [13]. - Shaanxi Tourism's investment projects include the construction of various tourism facilities, totaling 1.555 billion yuan [19]. - Haiseng Medical's investment projects focus on upgrading and expanding production capabilities for anesthesia and monitoring medical devices, with a total investment of 482.701 million yuan [24]. - Guoliang New Materials is involved in high-temperature industrial refractory materials, with a total investment of 175.022 million yuan for its projects [27].

Group 1 - The report highlights that as of June 8, 2025, the Beijing Stock Exchange (BSE) has accepted 98 companies, covering various sectors including high-end equipment manufacturing, TMT, chemical new materials, consumption, and biomedicine [3][12][13] - The focus is on selecting "back-up troops" from the new productivity sector, particularly those in intelligent connected new energy vehicles, hydrogen energy, new materials, innovative drugs, and commercial aerospace [3][4] - The report identifies six key companies: Yatu High-tech, Yuelong Technology, Daya Co., Yongli Precision, Haiseng Medical, and Haode CNC, which are recognized as national-level specialized and innovative "little giant" enterprises [5][23] Group 2 - Yatu High-tech specializes in high-performance industrial coatings, with a projected revenue of 742 million yuan and a net profit of 149 million yuan for 2024, reflecting a year-on-year revenue growth of 16.68% [28][34] - Yuelong Technology focuses on flexible pipelines for fluid transport, expecting a revenue of 262 million yuan and a net profit of 84 million yuan in 2024, with a revenue growth of 19.62% [5][24] - Daya Co. is a leader in metal surface treatment, with a projected revenue of 1.199 billion yuan and a net profit of 150.93 million yuan for 2024, showing a revenue increase of 23.86% [6][24] - Yongli Precision specializes in automotive shock absorber components, anticipating a revenue of 568 million yuan and a net profit of 94.81 million yuan in 2024, with a revenue growth of 11.72% [6][24] - Haiseng Medical produces anesthesia and monitoring medical devices, with expected revenue of 304 million yuan and a net profit of 70.92 million yuan for 2024, indicating a slight decline in revenue [6][24] - Haode CNC is recognized for its machinery used in panel furniture production, with a projected revenue of 458 million yuan and a net profit of 66.69 million yuan in 2024, reflecting a decrease in revenue [6][24]

Group 1 - Zhejiang Haisheng Medical Equipment Co., Ltd. (Haisheng Medical) has received approval for its IPO application, with CITIC Securities as the sponsor and Tianjian as the accounting firm [1] - Haisheng Medical specializes in the research, production, and sales of anesthesia and monitoring medical devices, serving clinical needs in various departments such as anesthesia, ICU, and emergency [1] - The company has established a sales network covering most provinces in China, with its products used in over 1,000 tertiary hospitals and thousands of medical institutions, including more than 600 top-tier hospitals [1] Group 2 - For the fiscal years 2022 to 2024, Haisheng Medical reported revenues of 267.72 million yuan, 305.88 million yuan, and 303.73 million yuan, respectively, with a net profit of 70.11 million yuan, 78.04 million yuan, and 70.92 million yuan [2] - In 2024, the company experienced a decline in both revenue and net profit, with revenue decreasing by 0.65% and net profit decreasing by 9.12% year-on-year [3] - As of March 2025, the company's total assets were 492 million yuan, a decrease of 0.82% from the previous year, while equity attributable to shareholders increased by 2.93% to 423 million yuan [3]

Group 1: IPO Applications - Beijing Stock Exchange accepted three IPO applications on May 29, 2025: Dalian Meidele (874489), Zhejiang Yongli Precision (874457), and Zhejiang Haiseng Medical (873794) [1] - As of now, a total of 12 companies have submitted IPO applications to the Beijing Stock Exchange in 2025 [1] Group 2: Dalian Meidele Industrial Automation Co., Ltd. - Dalian Meidele is a national high-tech enterprise specializing in the research, design, manufacturing, and sales of intelligent manufacturing equipment, primarily modular conveyor systems and industrial components [4] - The company has a registered capital of 56.123 million yuan and plans to list on the New Third Board on July 19, 2024 [3] - In 2024, the company expects to achieve a net profit of over 200 million yuan, with revenues of 1.138 billion yuan, and a net profit margin of 33.60% [6][7] - The company has a high customer concentration, with BYD being a major client, contributing 10.25% of total revenue in 2024 [9][10] - The IPO aims to raise 645 million yuan for four projects, including the construction of a new facility and R&D projects [12] Group 3: Zhejiang Yongli Precision Manufacturing Co., Ltd. - Zhejiang Yongli Precision focuses on the R&D, production, and sales of precision steel pipes and components for automotive applications, with a registered capital of 60 million yuan [14] - The company expects a net profit of 92.13 million yuan in 2024, with revenues projected at 568 million yuan [18][20] - The company has a high customer concentration, with BYD being the second-largest client in 2023 and 2024 [22][23] - The IPO plans to raise 380 million yuan for two projects, including the expansion of production capacity for chassis systems [26] Group 4: Zhejiang Haiseng Medical Device Co., Ltd. - Zhejiang Haiseng Medical specializes in the R&D, production, and sales of anesthesia and monitoring medical devices, with a registered capital of 64 million yuan [27] - The company anticipates a net profit of 68.04 million yuan in 2024, with revenues of approximately 304 million yuan [30][31] - The company has a low customer concentration, with the top five clients contributing only 21.66% of total revenue in 2024 [33] - The IPO aims to raise approximately 370.4 million yuan for three projects [34]